Advertisement

Topics

Dr. Reddy’s Laboratories Ltd. Company Profile

04:49 EDT 21st September 2017 | BioPortfolio

Unaudited Consolidated Income Statement


News Articles [448 Associated News Articles listed on BioPortfolio]

Dr. Reddy's Out-Licenses Plaque Psoriasis Drug to Encore Dermatology

NewsDr. Reddy's Laboratories announces the out-licensing of DFD-06 to Encore Dermatology. Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United...

Dr. Reddy's Laboratories Announces Out-Licensing of DFD-06 to Encore Dermatology

NewsThe drug is intended to be used for treatment of moderate to severe plaque psoriasis.

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Ltd. - RDY

NEW YORK, NY / ACCESSWIRE / September 11, 2017 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such inv...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 19, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ('Dr. Reddy's' or the 'Compan...

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 8, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" o...

EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 14, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Compan...

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 12, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" ...

Dr. Reddy’s and CHD Sign License Deal to Commercialize Surgical Infection Gel

NewsDr. Reddy’s and CHD Bioscience announce global license and commercialization agreement for Phase III clinical trial candidate for mitigation of surgical site infections.

PubMed Articles [189 Associated PubMed Articles listed on BioPortfolio]

Project management: importance for diagnostic laboratories.

The constraints applied on diagnostic laboratories to improve both quality and productivity together with personal shortages incite laboratory managers to constantly optimize the laboratory workflows,...

Cancer incidence in female laboratory employees: extended follow-up of a Swedish cohort study.

Work in chemical laboratories is associated with exposure to chemicals, of which some are known or suspected carcinogens. A cohort study of laboratory workers in Stockholm followed until 1992 showed a...

This Is not Participatory Design - A Critical Analysis of Eight Living Laboratories.

Design of Health Technology for elderly and care personnel has a high priority because of a severe increase of elderly citizens in need of health care combined with a decrease of resources in the heal...

Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories.

Genetic tests of the cancer predisposition genes BRCA1 and BRCA2 inform significant clinical decisions for both physicians and patients. Most uncovered variants are benign, and determining which few a...

CLSI-Based Validation of Manufacturer-Derived Reference Intervals on the Cobas 8000 Platform.

Reference intervals provided by diagnostic test manufacturers should be transferred to clinical laboratories after validation. Although protocols exist, laboratories rarely perform and report on resul...

Clinical Trials [248 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition

The objective of this study was to compare the single-dose relative bioavailability of Dr. Reddy's Laboratories, Ltd. and Merck & Co. (Propecia®) 1 mg finasteride tablets under fed condi...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition

The objective of this study was to compare the single-dose relative bioavailability of Dr. Reddy's Laboratories, Ltd. and Merck & Co. (Propecia®) 1 mg finasteride tablets under fasting c...

Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition

The purpose of this bioequivalence study is to compare a test Glimepiride 1 mg tablets of Dr.Reddy's Laboratories Limited versus reference Amaryl 1 mg tablets of Aventis Pharmaceuticals In...

Companies [936 Associated Companies listed on BioPortfolio]

Reddy US Therapeutics, Inc

Reddy US Therapeutics, Inc., part of Dr. Reddy's Discovery Research, was established in November 1999. Our company is located in the wooded suburbs of Atlanta. We currently occupy over 25000 sq. ft. o...

Dr. Reddy’s Laboratories

Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicine...

Dr. Reddy’s Laboratories Ltd.

Unaudited Consolidated Income Statement

Dr. Reddy's Laboratories

Established in 1984, Dr. Reddy’s Laboratories (NYSE:RDY) is an emerging global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicines...

Dr. Reddy's Laboratories Ltd.

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Thro...

More Information about "Dr. Reddy’s Laboratories Ltd." on BioPortfolio

We have published hundreds of Dr. Reddy’s Laboratories Ltd. news stories on BioPortfolio along with dozens of Dr. Reddy’s Laboratories Ltd. Clinical Trials and PubMed Articles about Dr. Reddy’s Laboratories Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dr. Reddy’s Laboratories Ltd. Companies in our database. You can also find out about relevant Dr. Reddy’s Laboratories Ltd. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record